September 4, 2012
Breakingviews: Valeant deal shows how big M&A can add value
By Robert Cyran
Large acquisitions usually merit skepticism. Valeant Pharmaceuticals International's $2.6 billion deal for Medicis Pharmaceutical looks like an exception. The Canadian-U.S. drug maker is paying...
If you already have a OnePass account, you can use it to access Business Law Currents as part of our free trial
program. If you don’t have a OnePass account, click on the link to the left to create one. You can then use this
OnePass account to access Business Law Currents as part of our free trial.